Abstract
We used a novel high-throughput drug screening assay, based on Luminex technology, to identify anti-myeloma agents capable of inhibiting cytokines and growth factors essential for multiple myeloma (MM) from a chemical library of 1120 compounds provided by MMRF. Tetracycline derivatives inhibited MM cell proliferation and osteoclast activating factors without obvious effect on cell viability. Steroid compounds specifically decreased angiogenesis-related factors, but stimulated osteoclast activating factors. Antihelmintic drugs potently inhibited cytokines and were cytotoxic. The screen identified potential candidates with potent anti-MM properties that need further investigation.
Copyright 2009 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adrenal Cortex Hormones / pharmacology
-
Anthelmintics / pharmacology
-
Anti-Infective Agents / pharmacology
-
Antineoplastic Agents / isolation & purification
-
Antineoplastic Agents / pharmacology*
-
Apoptosis / drug effects
-
B-Lymphocytes / drug effects
-
B-Lymphocytes / metabolism
-
Bone Marrow Cells / cytology
-
Bone Marrow Cells / drug effects
-
Cardiac Glycosides / pharmacology
-
Cell Differentiation / drug effects
-
Cell Line, Tumor / drug effects
-
Cell Line, Tumor / metabolism
-
Cytokines / antagonists & inhibitors*
-
Cytokines / metabolism
-
Drug Screening Assays, Antitumor / methods*
-
Growth Inhibitors / isolation & purification
-
Growth Inhibitors / pharmacology*
-
High-Throughput Screening Assays / methods*
-
Humans
-
Immunoassay / methods*
-
Microspheres
-
Multiple Myeloma / drug therapy*
-
Osteoclasts / cytology
Substances
-
Adrenal Cortex Hormones
-
Anthelmintics
-
Anti-Infective Agents
-
Antineoplastic Agents
-
Cardiac Glycosides
-
Cytokines
-
Growth Inhibitors